HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies MONTREAL, Feb. 25, 2026 ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
Pharmaceutical Technology on MSN
GSK sells liver disease drug candidate to Alfasigma for $690m
GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.
A major pharmaceutical company is leaving behind more than half a million square feet in a suburb of Washington, D.C. when its lease expires next year. London-based GSK is set to depart 635,000 square ...
GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...
Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results